<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Upadacitinib: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Upadacitinib: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Upadacitinib: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="122341" href="/d/html/122341.html" rel="external">see "Upadacitinib: Drug information"</a> and <a class="drug drug_patient" data-topicid="122342" href="/d/html/122342.html" rel="external">see "Upadacitinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F53551384"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious infections:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Patients treated with upadacitinib are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt upadacitinib until the infection is controlled. Reported infections include:</p>
<p style="text-indent:-2em;margin-left:6em;">Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before upadacitinib use and during therapy. Treatment for latent infection should be considered prior to upadacitinib use.</p>
<p style="text-indent:-2em;margin-left:6em;">Invasive fungal infections, including cryptococcosis and pneumocystosis.</p>
<p style="text-indent:-2em;margin-left:6em;">Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.</p>
<p style="text-indent:-2em;margin-left:4em;">The risks and benefits of treatment with upadacitinib should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with upadacitinib, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients ≥50 years of age with ≥1 cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancies:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lymphoma and other malignancies have been observed in patients treated with upadacitinib. In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding nonmelanoma skin cancer) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Major adverse cardiovascular events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">In RA patients ≥50 years of age with ≥1 cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (defined as cardiovascular death, myocardial infarction [MI], and stroke) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue upadacitinib in patients that have experienced an MI or stroke.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis have occurred in patients treated with JAK inhibitors used to treat inflammatory conditions. Many of these adverse events were serious and some resulted in death. In RA patients ≥50 years of age with ≥1 cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers. Avoid upadacitinib in patients at risk. Patients with symptoms of thrombosis should discontinue upadacitinib and be promptly evaluated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53559872"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rinvoq</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54127872"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Rinvoq</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56565761"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antirheumatic Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Antirheumatic, Disease Modifying</span>;</li>
<li>
<span class="list-set-name">Janus Kinase Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F56565767"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do not initiate therapy in patients with an absolute lymphocyte count (ALC) &lt;500/mm<sup>3</sup>, ANC &lt;1,000/mm<sup>3</sup>, or hemoglobin &lt;8 g/dL. Prior to initiation of therapy, patients should be screened for tuberculosis and viral hepatitis; ensure immunizations are up to date.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1cb01b0a-9408-444e-899b-06d8a273579d">Atopic dermatitis, refractory, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis, refractory, moderate to severe:</b> Children ≥12 years and Adolescents, weighing ≥40 kg: Oral: 15 mg once daily; may increase to 30 mg once daily if inadequate response; in clinical trials, used as either monotherapy or in combination with topical corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34023008','lexi-content-ref-34988493','lexi-content-ref-34023009','lexi-content-ref-34403658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34023008','lexi-content-ref-34988493','lexi-content-ref-34023009','lexi-content-ref-34403658'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage</b>
<b> adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b> Children ≥12 years and Adolescents, weighing ≥40 kg:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematologic:</i></p>
<p style="text-indent:-2em;margin-left:6em;">ALC &lt;500/mm<sup>3</sup>: Interrupt therapy until ALC ≥500/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">ANC &lt;1,000/mm<sup>3</sup>: Interrupt therapy until ANC ≥1,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemoglobin &lt;8 g/dL: Interrupt therapy until hemoglobin ≥8 g/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hypersensitivity reaction (severe):</i> Discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Infection (serious), including herpes zoster</i>: Interrupt treatment until the infection is controlled.</p></div>
<div class="block dorp drugH1Div" id="F56565768"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents, weighing ≥40 kg: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: 15 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Use not recommended.</p></div>
<div class="block dohp drugH1Div" id="F56565769"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents, weighing ≥40 kg: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Baseline hepatic impairment: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Mild to moderate impairment: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">Severe impairment: Use is not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hepatotoxicity <b>during </b>treatment:</i> Treatment should be interrupted if drug-induced liver injury is suspected.</p></div>
<div class="block doa drugH1Div" id="F53583794"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="122341" href="/d/html/122341.html" rel="external">see "Upadacitinib: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Do <b>not</b> use in combination with biologic disease-modifying antirheumatic drugs (DMARDs) or potent immunosuppressants (eg, azathioprine, cyclosporine); do <b>not</b> initiate in patients with an absolute lymphocyte count &lt;500/mm<sup>3</sup>, ANC &lt;1,000/mm<sup>3</sup>, or Hb &lt;8 g/dL.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62637659-f98d-4a3f-aec5-dbd1f84dc2b2">Ankylosing spondylitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ankylosing spondylitis: Oral:</b> 15 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67e9e2b-6dad-418d-9ecc-84f4de0f5978">Atopic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis: Oral:</b> 15 mg once daily; may increase to 30 mg once daily if inadequate response. Discontinue if an adequate response is not achieved with the 30 mg dose; use the lowest effective dose needed to maintain response.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="698502f2-8371-4f7b-b52e-f26b1c2278b7">Crohn disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease: Oral: </b>Induction: 45 mg once daily for 12 weeks; maintenance: 15 mg once daily; may increase to 30 mg once daily in patients with refractory, severe, or extensive disease. Discontinue if an adequate response is not achieved with the 30 mg dose; use the lowest effective dose needed to maintain response.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f086440-d826-408b-a554-385b730eadc9">Nonradiographic axial spondyloarthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Nonradiographic axial spondyloarthritis: Oral:</b> 15 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis: Oral:</b> 15 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use as adjunctive therapy in patients who have not met treatment goals despite maximally tolerated methotrexate therapy; may also be used off-label as an alternative to methotrexate in DMARD–naive patients with moderate to high disease activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 15 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e147f438-ac03-44c7-98c9-bf0acd598ea0">Ulcerative colitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis: Oral:</b> Induction: 45 mg once daily for 8 weeks; maintenance: 15 mg once daily; may increase to 30 mg once daily in patients with refractory, severe, or extensive disease. Discontinue if an adequate response is not achieved with the 30 mg dose; use the lowest effective dose needed to maintain response.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F53583799"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ankylosing spondylitis, nonradiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥15 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: 15 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: Induction: 30 mg once daily for 12 weeks; maintenance: 15 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: Induction: 30 mg once daily for 8 weeks; maintenance: 15 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F53583800"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment <b>prior </b>to treatment initiation:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ankylosing spondylitis, atopic dermatitis, nonradiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment (Child-Pugh class C): Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Crohn disease:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate impairment (Child-Pugh class A or B): Induction: 30 mg once daily for 12 weeks; maintenance: 15 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment (Child-Pugh class C): Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ulcerative colitis</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate impairment (Child-Pugh class A or B): Induction: 30 mg once daily for 8 weeks; maintenance: 15 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment (Child-Pugh class C): Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity <b>during </b>treatment: Treatment should be interrupted if drug-induced liver injury is suspected.</p></div>
<div class="block adr drugH1Div" id="F53778649"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and adolescents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (1% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (9% to 25%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Folliculitis (2% to 4%), skin carcinoma (≤1%; including non-melanoma), skin rash (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (2% to 4%), hyperlipidemia (2%), weight gain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2% to 3%), gastroenteritis (3%), nausea (3% to 4%), oral candidiasis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (7%), leukopenia (1% to 2%), lymphocytopenia (3%), neutropenia (1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (including cholestasis, drug-induced liver injury, increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, and increased serum bilirubin: ≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (≤8%), herpes zoster infection (1% to 5%), influenza (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (2% to 3%), headache (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (1% to 8%), myalgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (1% to 4%), cough (2% to 3%), flu-like symptoms (2%), pneumonia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal perforation, oral herpes simplex infection</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinal detachment</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thrombosis, deep vein thrombosis, pulmonary embolism, thrombosis, venous thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis, eczema (herpeticum), varicella-like rash (Kaposi varicelliform eruption)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Esophageal candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant neoplasm</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including bacterial infection, cryptococcosis, fungal infection, opportunistic infection, serious infection, viral infection), reactivation of HBV</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Infection due to an organism in genus <i>Pneumocystis</i>, tuberculosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (FDA Safety Alert September 1, 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant lymphoma (FDA Safety Alert September 1, 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident (FDA Safety Alert September 1, 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Lung carcinoma (FDA Safety Alert September 1, 2021)</p></div>
<div class="block coi drugH1Div" id="F53551389"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to upadacitinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F53583776"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• GI perforation: Use with caution in patients at increased risk for GI perforation (eg, history of diverticulitis, concomitant nonsteroidal anti-inflammatory drugs, corticosteroids); perforations have been reported in clinical trials. Promptly evaluate new-onset abdominal symptoms in patients taking upadacitinib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic toxicity: Hematologic toxicity, including lymphopenia, anemia, and neutropenia, may occur and is generally reversible and managed by treatment interruption. Do not initiate therapy in patients with an absolute lymphocyte count &lt;500/mm<sup>3</sup>, ANC &lt;1,000/mm<sup>3</sup>, or hemoglobin &lt;8 g/dL. Monitor CBC at baseline and periodically thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Liver enzyme elevation has been observed. Monitor LFTs at baseline and periodically thereafter; interrupt therapy if LFTs increased and drug-induced liver injury is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe hypersensitivity, including anaphylaxis and angioedema, has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Patients receiving upadacitinib are at increased risk for serious infections, which may result in hospitalization and/or fatality; rate of serious infections was increased in patients on higher doses. The most common serious infections reported included pneumonia and cellulitis. Reactivation of viral infections (eg, herpes zoster, hepatitis B) have been observed; the incidence of chronic viral hepatitis reactivation is unknown. If herpes zoster is reported, consider interrupting therapy until herpes zoster has resolved. Consultation with a hepatologist may be necessary if hepatitis B virus DNA is detected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid abnormalities: Increased lipid parameters (eg, total, low-density lipoprotein [LDL], and high-density lipoprotein [HDL] cholesterol) have been observed. Mean LDL and HDL increased by ~15 mg/dL and ~8 mg/dL, respectively, 2 months after starting upadacitinib. Assess lipids 12 weeks after upadacitinib initiation and manage lipid abnormalities according to current clinical guidelines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Lymphoma and other malignancies have been reported in patients receiving upadacitinib. Consider risks versus benefits prior to use in patients with a known malignancy (other than successfully treated nonmelanoma skin cancers [NMSCs]) or when continuing upadacitinib in patients who develop a new malignancy. NMSCs have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Medication residue in stool: Medication residue in stool or ostomy output has been reported in patients with anatomical conditions (eg, ileostomy, colostomy, intestinal resection) or functional conditions that slow GI transit times. Instruct patients to report medication residue in stool to a health care provider. Monitor patients for clinical response and consider alternative therapy if there is a lack of therapeutic response.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tuberculosis: Tuberculosis (TB) (pulmonary or extrapulmonary) has been reported in patients receiving upadacitinib. Use with caution in patients who have resided or traveled in regions where TB is endemic. Consider anti-TB therapy if an adequate course of treatment cannot be confirmed in patients with a history of TB infection or disease (latent or active TB) or for patients with risk factors despite negative skin test.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold upadacitinib for at least 3 days prior to surgery to reduce infection risk; therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk) (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Immunization status should be current before initiating therapy. Live vaccines should not be given concomitantly, or immediately prior to, upadacitinib; recommended interval between receipt of live vaccines and initiation of immunosuppressive agents such as upadacitinib should follow current vaccination clinical guidelines.</p></div>
<div class="block foc drugH1Div" id="F53559873"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rinvoq: 15 mg, 30 mg, 45 mg</p></div>
<div class="block geq drugH1Div" id="F53559871"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53685433"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Rinvoq Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $257.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $257.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $514.49</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54127873"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rinvoq: 15 mg, 30 mg, 45 mg</p></div>
<div class="block admp drugH1Div" id="F56565770"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food. Swallow tablet whole; do not crush, split, or chew.</p></div>
<div class="block adm drugH1Div" id="F53583802"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food. Swallow tablet whole; do not crush, split, or chew.</p></div>
<div class="block hazard drugH1Div" id="F53715932"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Upadacitinib may cause carcinogenicity and teratogenicity.</p>
<p style="text-indent:-2em;margin-left:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets (NIOSH 2016). Facilities may perform assessment of some (non-antineoplastic) hazardous drugs to determine if appropriate for alternative containment strategies and handling requirements; assess risk to determine appropriate containment strategy (USP-NF 2018).</p></div>
<div class="block sts drugH1Div" id="F53583780"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 25°C (36°F to 77°F). Store in the original bottle to protect from moisture.</p></div>
<div class="block meg drugH1Div" id="F54684460"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Rinvoq: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F211675s019lbl.pdf%23page%3D72&amp;token=p%2BwsoNiN%2BWqbtfOJiVKMkymB94h6Tz79SHNO1HfOw39JjbICjyoU%2ByldY7ChkiGMs20lUtNtsI8d8K%2FlR%2Bb8kQS1MonCzxgHnMt9Hj0NVFSP3pT53Sx%2B%2By6GrMwIWiJf&amp;TOPIC_ID=134956" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211675s019lbl.pdf#page=72</a></p></div>
<div class="block usep drugH1Div" id="F56565765"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of refractory, moderate to severe atopic dermatitis in patients with an inadequate response or intolerance to other systemic drug products, including biologics, or when use of those therapies is inadvisable (FDA approved in ages ≥12 years and adults); treatment of active psoriatic arthritis in patients with an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers (FDA approved in adults); treatment of moderately to severely active rheumatoid arthritis in patients with an inadequate response or intolerance to one or more TNF blockers (FDA approved in adults); treatment of moderately to severely active ulcerative colitis in patients with an inadequate response or intolerance to one or more TNF blockers (FDA approved in adults); treatment of active nonradiographic axial spondyloarthritis in patients with objective signs of inflammation who had an inadequate response or intolerance to TNF blockers (FDA approved in adults).</p></div>
<div class="block cyt drugH1Div" id="F53587349"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> BCRP/ABCG2, CYP3A4 (weak), OATP1B1/1B3 (SLCO1B1/1B3)</p></div>
<div class="block dri drugH1Div" id="F53587346"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the immunosuppressive effect of Upadacitinib. Management: Coadministration of upadacitinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Upadacitinib may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Rheumatology guidelines recommend holding baricitinib, tofactinib, or upadacitinib for 1 to 2 weeks after vaccine administration as permitted by the underlying disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Substrates (Narrow Therapeutic Index/Sensitive): Upadacitinib may increase the serum concentration of CYP2D6 Substrates (Narrow Therapeutic Index/Sensitive). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Upadacitinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Upadacitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Upadacitinib. Management: Upadacitinib dose adjustments are needed when combined with strong CYP3A4 inhibitors. Specific adjustments vary based on upadacitinib indication. See full interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Upadacitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the immunosuppressive effect of Upadacitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the immunosuppressive effect of Upadacitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the immunosuppressive effect of Upadacitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the immunosuppressive effect of Upadacitinib. Management: Concomitant use of upadacitinib with high-dose or IV methotrexate is not recommended. Use with antirheumatic doses of methotrexate is permitted, and if combined, patients should be monitored for infection.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zavegepant: OATP1B1/1B3 (SLCO1B1/1B3) Inducers may decrease the serum concentration of Zavegepant. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F58097080"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit increases exposure to upadacitinib. Management: Avoid grapefruit during therapy.</p></div>
<div class="block dic drugH1Div" id="F58097081"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F53583774"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use adequate contraception during treatment and for 4 weeks following the last dose of upadacitinib.</p></div>
<div class="block pri drugH1Div" id="F53583773"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Based on data from animal reproduction studies, in utero exposure to upadacitinib may cause fetal harm.</p>
<p style="text-indent:-2em;margin-left:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to upadacitinib is ongoing. Health care providers should report patients exposed to upadacitinib during pregnancy by calling 1-800-633-9110.</p></div>
<div class="block mopp drugH1Div" id="F56565771"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Absolute lymphocyte count, ANC, hemoglobin, and LFTs (baseline and periodically thereafter); serum lipids panel (12 weeks after therapy initiation and periodically thereafter); viral hepatitis screening (prior to initiating therapy and periodically thereafter); latent and active tuberculosis (TB) screen at baseline; verify pregnancy status (prior to initiating therapy); signs/symptoms of infection (including TB) during and after therapy; skin examinations (periodically, in patients at increased risk for skin cancer); symptoms of thrombosis.</p></div>
<div class="block pha drugH1Div" id="F53583781"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Upadacitinib inhibits Janus kinase (JAK) enzymes, which are intracellular enzymes involved in stimulating hematopoiesis and immune cell function through a signaling pathway. JAKs activate signal transducers and activators of transcription (STATs), which regulate gene expression and intracellular activity. The inhibition of JAKs prevents the activation of STATs.</p></div>
<div class="block phk drugH1Div" id="F53583782"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 52% (plasma proteins)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, primarily via CYP3A4</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 8 to 14 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (24% as unchanged drug); feces (38% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F53583791"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC<sub>inf </sub>18%, 33%, and 44% higher in mild, moderate, and severe renal impairment, respectively, compared to subjects with normal renal function. C<sub>max</sub> similar in subjects with normal and impaired renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC<sub>inf</sub> 28% and 24% higher in mild and moderate hepatic impairment, respectively, compared to subjects with normal hepatic function. C<sub>max</sub> unchanged in mild hepatic impairment and 43% higher in moderate hepatic impairment compared to subjects with normal hepatic function. Not studied in patients with severe hepatic impairment (Child-Pugh C).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F54519586"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Rematib</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Rinvoq</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2018:84-103.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/upadacitinib-pediatric-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/upadacitinib-pediatric-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34023008">
<a name="34023008"></a>Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. <i>Lancet</i>. 2021;397(10290):2151-2168. doi:10.1016/S0140-6736(21)00588-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/upadacitinib-pediatric-drug-information/abstract-text/34023008/pubmed" id="34023008" target="_blank">34023008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34988493">
<a name="34988493"></a>Katoh N, Ohya Y, Murota H, et al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis. <i>JAAD Int</i>. 2021;6:27-36. doi:10.1016/j.jdin.2021.11.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/upadacitinib-pediatric-drug-information/abstract-text/34988493/pubmed" id="34988493" target="_blank">34988493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34023009">
<a name="34023009"></a>Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i>. 2021;397(10290):2169-2181. doi:10.1016/S0140-6736(21)00589-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/upadacitinib-pediatric-drug-information/abstract-text/34023009/pubmed" id="34023009" target="_blank">34023009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rinvoq.1">
<a name="Rinvoq.1"></a>Rinvoq (upadacitinib) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34403658">
<a name="34403658"></a>Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. <i>J Allergy Clin Immunol</i>. Published online August 14, 2021. doi:10.1016/j.jaci.2021.07.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/upadacitinib-pediatric-drug-information/abstract-text/34403658/pubmed" id="34403658" target="_blank">34403658</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed September 17, 2019.</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration (FDA). FDA Safety Alert. MedWatch. Xeljanz, Xeljanz XR (tofacitinib): FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death</a>. Accessed September 2, 2021</div>
</li></ol></div><div id="topicVersionRevision">Topic 134956 Version 67.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
